Status: Recruiting
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
This is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.
Participants needed: 42
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: D3 Bio (Wuxi) Co., LtdUpdated: Jun 4, 2026Locations: 5
Eligibility criteria
Subjects must have histologically confirmed locally advanced, recurrent, or meta... [+4]
Participant has any prior treatment with a specific KRAS G12D inhibitor/degrader... [+3]